STRADB anticorps (C-Term)
Aperçu rapide pour STRADB anticorps (C-Term) (ABIN391172)
Antigène
Voir toutes STRADB AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 274-303, C-Term
-
Purification
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
Immunogène
- This ALS2CR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-303 amino acids from the C-terminal region of human ALS2CR2.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
-
Date de péremption
- 6 months
-
-
- STRADB (STE20-Related Kinase Adaptor beta (STRADB))
-
Autre désignation
- ALS2CR2
-
Sujet
- ALS2CR2 potentiates the antiapoptotic activity of XIAP by enhancing XIAP-mediated activation of JNK1 (MAPK8) and other JNK family members, but not by modulating XIAP-mediated caspase inhibition. Expression of a catalytically inactive TAK1 (MAP3K7) mutant blocks the XIAP/ALS2CR2 activation of JNK1. In vivo coprecipitation experiments show that both ALS2CR2 and XIAP interact with TAK1 and TRAF6. It has been proposed that XIAP-mediated protection from apoptosis utilizes both a JNK1 activation pathway that involves ALS2CR2 and a caspase inhibition pathway that is independent of ALS2CR2.
-
Poids moléculaire
- 47026
-
ID gène
- 55437
-
NCBI Accession
- NP_001193793, NP_061041
-
UniProt
- Q9C0K7
-
Pathways
- AMPK Signaling
Antigène
-